Fig 1.
Hierarchical Clustering of 1,593 breast tumor samples using the 60 genes identified as differentially expressed between CL tumors and tumors of all other molecular subtypes
Table 1.
Genes differentially expressed between CL tumors and all other molecular subtypes of breast cancer using gene-expression profiling.
Table 2.
Expression of Immunohistochemical Markers in Breast Cancer Cell Lines.
Fig 2.
Representative H&E stained image of luminal A [A], luminal B [B], HER2 [C], basal [D] and Claudin-low [E] tumors. ER staining in luminal A [F], luminal B [G], HER2 [H], basal [I] and Claudin-low [J] tumors. PR staining in luminal A [K], luminal B [L], HER2 [M], basal [N] and Claudin-low [O] tumors. HER2 staining in luminal A [P], luminal B [Q], HER2 [R], basal [S] and Claudin-low [T] tumors. Ki67 staining in luminal A [U], luminal B [V], HER2 [W], basal [X] and Claudin-low [Y] tumors. EGFR staining in luminal A [Z], luminal B [AA], HER2 [BB], basal [CC] and Claudin-low [DD] tumors. CK5 staining in luminal A [EE], luminal B [FF], HER2 [GG], basal [HH] and Claudin-low [II] tumors. Claudin-3 staining in luminal A [JJ], luminal B [KK], HER2 [LL], basal [MM] and Claudin-low [NN] tumors. Claudin-4 staining in luminal A [OO], luminal B [PP], HER2 [QQ], basal [RR] and Claudin-low [SS] tumors. Claudin-7 staining in luminal A [TT], luminal B [UU], HER2 [VV], basal [WW] and Claudin-low [XX] tumors. E-cadherin staining in luminal A [YY], luminal B [ZZ], HER2 [AAA], basal [BBB] and Claudin-low [CCC] tumors.
Table 3.
Clinical-pathologic Characteristics of Invasive Breast Cancers According to Molecular Subtypes in the TMA cohort.
Fig 3.
Disease-Free Survival (DFS) of Patients enrolled in the AHWBI trial by Tumor Subtype
Fig 4.
Overall Survival (OS) of Patients enrolled in the AHWBI trial by Tumor Subtype
Fig 5.
Local Recurrence (LR) of Patients enrolled in the AHWBI trial by Tumor Subtype